Atlas Trials

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT06845241 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06845241
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Non-Hodgkin Lymphoma
Start date
2025-02-01
Primary completion
2028-07-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.